HTBX : Summary for Heat Biologics, Inc. - Yahoo Finance

U.S. Markets closed

Heat Biologics, Inc. (HTBX)


NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.80-0.04 (-4.18%)
At close: 4:00PM EST
People also watch
NVCNEVOKEBIOSPHSIMNP
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close0.84
Open0.84
Bid0.65 x 3000
Ask0.85 x 500
Day's Range0.71 - 0.84
52 Week Range0.40 - 3.35
Volume1,159,668
Avg. Volume2,813,708
Market Cap21.34M
Beta1.38
PE Ratio (TTM)-0.70
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • American City Business Journals4 days ago

    Heat Biologics offers further bladder cancer treatment outlook

    After announcing disappointing Phase 2 bladder cancer treatment results in November , Durham’s Heat Biologics presented data from its trial at the Genitourinary Cancers Symposium in Orlando last week, along with company outlook in the space. “As previously reported, vaccine arms did not show a statistical improvement over the placebo arm in the primary endpoint (1-year recurrence free survival). In an interview in December, CEO Jeff Wolf said that the two-year endpoint will allow the company “to get a better look at the data as it matures …” He added that the company will then determine whether to progress its treatment HS-410 to Phase 3 trials.

  • GlobeNewswire9 days ago

    Heat Biologics Presents Immune Data on its HS-410 Phase 2 Bladder Cancer Trial at the Genitourinary Cancers Symposium

    DURHAM, N.C., Feb. 17, 2017-- Heat Biologics, Inc., announced that it presented a poster of its immunological data from its 94- patient Phase 2 trial evaluating vesigenurtacel-L either alone or in combination ...

  • GlobeNewswire12 days ago

    Heat Biologics to Present at the Genitourinary Cancers Symposium

    DURHAM, N.C., Feb. 14, 2017-- Heat Biologics, Inc., a leader in the development of immunotherapies designed to activate a patient’ s immune system against cancer, announced that it will present a poster ...